NASDAQ$ANTX
AN2 Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
AN2 Therapeutics reported results for the third quarter of 2024, provided an update on EBO-301, and highlighted progress across its boron chemistry pipeline.
AN2 Therapeutics reported a net loss of $12.7 million for Q3 2024. Epetraborole-treated patients showed clinical improvements in QOL-B and MACrO2. The company plans to meet with the FDA to discuss the development path for epetraborole and is advancing its boron chemistry pipeline. They also achieved a 50% reduction in expenditures and have a cash runway through 2027.
- Epetraborole demonstrated clinical improvements in QOL-B and a post-hoc analysis of MACrO2 in TR-MAC patients.
- The company plans to meet with the FDA to discuss the development path for epetraborole, including potentially reinitiating a Phase 3 clinical study.
- AN2 Therapeutics achieved a 50% reduction in expenditures through a strategic realignment of operations.
- Cash, cash equivalents, and investments totaled $93.4 million at the end of Q3 2024, expected to fund operations through 2027.
Headline financials
Revenue & EPS history
AN2 Therapeutics · Revenue · Quarterly
$0
Forward guidance
AN2 Therapeutics is focused on advancing its boron chemistry platform and plans to initiate Phase 1 clinical development with AN2-502998 in mid-2025. The company also completed enrollment in a 200-patient observational trial for epetraborole in acute melioidosis in October 2024 and these data will inform a Phase 2 proof of concept study that is planned to initiate enrollment in the second half of 2025.
Tailwinds
- Advancing preclinical activities aimed to initiate clinical studies in chronic Chagas disease with AN2-502998 in mid-2025.
- Completed enrollment in a 200-patient observational trial for epetraborole in acute melioidosis in October 2024.
- Planning to initiate enrollment in a Phase 2 proof of concept study for melioidosis in the second half of 2025.
- Delivering up to three development compounds in 2025.
- Continuing efforts to tackle global health disease through non-dilutive funding from the Bill & Melinda Gates Foundation.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
+8.9%
Avg return
Earnings day
+14.4%
Avg return
5 days after
-1.6%
Avg return
30 days after
47%
9 / 19 earnings
Positive
+75.2%
Q2 2021
Best reaction
-6.2%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.9% | +0.8% | -5.7% | |
| Q3 2025 | -4.3% | -5.1% | +1.7% | |
| Q2 2024 | +1.9% | +6.2% | +21.3% | |
| Q2 2025 | +0.0% | +6.2% | +21.3% | |
| Q1 2025 | -1.7% | -1.7% | -10.7% | |
| Q4 2024 | -2.4% | -9.3% | -16.7% | |
| Q3 2024 | -5.7% | -5.7% | +34.9% | |
| Q1 2024 | -3.4% | -3.4% | -15.3% | |
| Q4 2023 | +16.8% | +5.6% | -28.0% | |
| Q3 2023 | -6.2% | +4.5% | +23.2% | |
| Q2 2023 | +2.8% | +5.4% | +90.1% | |
| Q1 2023 | +0.4% | +46.2% | +48.5% | |
| Q4 2022 | +1.8% | +4.8% | -17.0% | |
| Q3 2021 | -3.5% | -3.3% | -41.4% | |
| Q3 2022 | -3.5% | -3.3% | -41.4% | |
| Q2 2022 | +75.2% | +95.8% | -14.6% | |
| Q2 2021 | +75.2% | +95.8% | -14.6% | |
| Q4 2021 | +14.2% | +16.9% | -32.9% | |
| Q1 2022 | +14.2% | +16.9% | -32.9% | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro